Designing multi-target drugs
"Multi-target drug discovery (MTDD) is an emerging area of increasing interest to the drug discovery community. Drugs that modulate several targets have the potential for an improved balance of efficacy and safety compared to single targets agents. Although there are a number of marketed drugs...
Saved in:
| Other Authors | , |
|---|---|
| Format | Electronic eBook |
| Language | English |
| Published |
Cambridge, U.K. :
Royal Society of Chemistry,
2012.
|
| Series | RSC drug discovery series ;
21. |
| Subjects | |
| Online Access | Full text |
| ISBN | 9781849734912 9781621981435 9781849733625 |
| Physical Description | 1 online zdroj (xxvii, 365 p.) : ill. |
Cover
| LEADER | 00000cam a2200000 a 4500 | ||
|---|---|---|---|
| 001 | 82325 | ||
| 003 | CZ-ZlUTB | ||
| 005 | 20251008100940.0 | ||
| 006 | m o d | ||
| 007 | cr |n | ||
| 008 | 120425s2012 enka sb 001 0 eng d | ||
| 020 | |a 9781849734912 |q (ebook) | ||
| 020 | |a 9781621981435 |q (ebook) | ||
| 020 | |a 9781849733625 | ||
| 035 | |a (OCoLC)789150271 |z (OCoLC)785730758 |z (OCoLC)788647207 |z (OCoLC)810436453 |z (OCoLC)843641057 | ||
| 040 | |a UKRSC |b eng |c UKRSC |d COO |d UIU |d MYG |d KNOVL |d YDXCP |d N$T |d ZCU |d OHS |d KNOVL |d OCLCF |d KNOVL |d NLGGC |d KNOVL |d MHW |d OCLCQ | ||
| 245 | 0 | 0 | |a Designing multi-target drugs |h [elektronický zdroj] / |c editors, J. Richard Morphy and C. John Harris. |
| 260 | |a Cambridge, U.K. : |b Royal Society of Chemistry, |c 2012. | ||
| 300 | |a 1 online zdroj (xxvii, 365 p.) : |b ill. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a počítač |b c |2 rdamedia | ||
| 338 | |a online zdroj |b cr |2 rdacarrier | ||
| 490 | 1 | |a RSC drug discovery ; |v 21 | |
| 504 | |a Includes bibliographical references and index. | ||
| 520 | |a "Multi-target drug discovery (MTDD) is an emerging area of increasing interest to the drug discovery community. Drugs that modulate several targets have the potential for an improved balance of efficacy and safety compared to single targets agents. Although there are a number of marketed drugs that are thought to derive their therapeutic benefit by virtue of interacting with multiple targets, the majority of these were discovered accidentally. Written by world renowned experts, this is the first book to gather together knowledge and experiences of the rational discovery of multi-target drugs. It describes the current state of the art, the achievements and the challenges of the field and importantly the lessons learned by researchers to date and their application to future MTDD."-- |c Provided by publisher. | ||
| 590 | |a Knovel Library |b ACADEMIC - Pharmaceuticals, Cosmetics & Toiletries | ||
| 506 | |a Plný text je dostupný pouze z IP adres počítačů Univerzity Tomáše Bati ve Zlíně nebo vzdáleným přístupem pro zaměstnance a studenty univerzity | ||
| 650 | 0 | |a Drugs |x Design. | |
| 650 | 0 | |a Drug targeting. | |
| 655 | 7 | |a elektronické knihy |7 fd186907 |2 czenas | |
| 655 | 9 | |a electronic books |2 eczenas | |
| 700 | 1 | |a Morphy, Richard. | |
| 700 | 1 | |a Harris, C. John. | |
| 776 | 0 | 8 | |i Print version: |t Designing multi-target drugs. |d Cambridge : Royal Society of Chemistry, 2012 |z 9781849733625 |w (OCoLC)779245878 |
| 830 | 0 | |a RSC drug discovery series ; |v 21. | |
| 856 | 4 | 0 | |u https://proxy.k.utb.cz/login?url=http://app.knovel.com/hotlink/toc/id:kpDMTD0003/designing_multitarget_drugs |
| 992 | |a BK |c KNOVEL | ||
| 999 | |c 82325 |d 82325 | ||
| 993 | |x NEPOSILAT |y EIZ | ||